Biomarkers as Predictive Factors of Anti-VEGF Response

Biomedicines

Rafael Peláez¹  Ana Pariente¹  Ignacio M. Larráyoz¹  Álvaro Pérez-Sala¹  Ana I. Oca¹  Miriam Bobadilla¹ 

[1] Biomarkers and Molecular Signaling Group, Neurodegenerative Diseases Area Center for Biomedical Research of La Rioja, CIBIR, 26006 Logroño, Spain;

关键词: age-related macular degeneration;    ranibizumab;    aflibercept;    brolucizumab;    anti-VEGF;    SNPs;   

DOI  :  10.3390/biomedicines10051003

来源: DOAJ

【 摘 要 】

Age-related macular degeneration is the main cause of irreversible vision in developed countries, and intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are the current gold standard treatment today. Although anti-VEGF treatment results in important improvements in the course of this disease, there is a considerable number of patients not responding to the standardized protocols. The knowledge of how a patient will respond or how frequently retreatment might be required would be vital in planning treatment schedules, saving both resource utilization and financial costs, but today, there is not an ideal biomarker to use as a predictive response to ranibizumab therapy. Whole blood and blood mononuclear cells are the samples most studied; however, few reports are available on other important biofluid samples for studying this disease, such as aqueous humor. Moreover, the great majority of studies carried out to date were focused on the search for SNPs in genes related to AMD risk factors, but miRNAs, proteomic and metabolomics studies have rarely been conducted in anti-VEGF-treated samples. Here, we propose that genomic, proteomic and/or metabolomic markers could be used not alone but in combination with other methods, such as specific clinic characteristics, to identify patients with a poor response to anti-VEGF treatment to establish patient-specific treatment plans.

【 授权许可】

Unknown